Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my outlook of MENS stock prospects.
Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle (MENS)
Friday, 25 Apr 2025
Exclusive insights, data, and analysis for financial market experts.
Search
Have an existing account?
Sign In
